Approaches to Reducing Toxicity and Side Effects in Cell and Gene Therapy

Why It Matters

Reducing toxicity unlocks broader patient access, supports outpatient delivery, and sustains the high‑growth trajectory of the cell‑gene therapy market.

Key Takeaways

• BMS data: >95% of CRS events happen within first two weeks
• CytoAgents' CTO1681 cuts TNF‑α, IL‑6 without harming CAR efficacy
• Sarepta adds sirolimus to Elevidys to mitigate liver injury
• Cartesian's mRNA BCMA CAR shows no CRS or ICANS in MG trial
• Anito‑cel D‑domain CAR achieves 97% response with low‑grade CRS

Pulse Analysis

The cell and gene therapy sector is at a crossroads where clinical promise meets safety scrutiny. While CAR‑T and AAV platforms have delivered breakthrough outcomes for cancers and rare diseases, the incidence of cytokine release syndrome and neurotoxicity has limited their use to specialized centers. Investors and regulators alike are watching how manufacturers address these risks, because a safer profile directly translates into larger patient pools, shorter hospital stays, and lower overall treatment costs.

Recent advances illustrate a multi‑pronged approach. Oral prostaglandin‑E2 inhibitors such as CytoAgents' CTO1681 demonstrate pre‑clinical suppression of key cytokines without compromising tumor killing, paving the way for outpatient CAR‑T administration. Parallelly, traditional immunosuppressants like sirolimus are being repurposed to protect the liver during AAV‑based gene delivery, as seen in Sarepta's Elevidys trials for Duchenne muscular dystrophy. These pharmacologic safeguards aim to convert high‑intensity infusion protocols into manageable, scalable therapies.

Beyond drugs, engineering innovations are reshaping the cellular product itself. mRNA‑encoded CARs from Cartesian Therapeutics avoid viral integration and the associated chemotherapy conditioning, delivering comparable efficacy with negligible CRS in myasthenia gravis patients. Likewise, D‑domain engineered CARs such as anito‑cel achieve near‑complete response rates in multiple myeloma while limiting neurological side effects. Collectively, these strategies signal a maturation of the field, where safety and efficacy converge to unlock the next wave of commercial growth.